Research
Hormonal
Anti-obesity vaccines are primarily in preclinical to Phase II stages, with candidates like ghrelin vaccines showing up to 15% reduced weight gain in preclinical models.
Ghrelin vaccines may be a promising avenue for reducing weight gain in future therapies.
StrongSupportsmedium confidence
Anti-obesity vaccines are primarily in preclinical to Phase II stages, with candidates like ghrelin vaccines (e.g., CYT009-GhrQb) showing up to 15% reduced weight gain in preclinical models.
Why this rating
Based on the review of multiple studies and trials.
Source
Biopharma Evaluation of Anti-Obesity Vaccines in Global Trials by Dr. Slim™
Reza Ghalamghash · Preprints.org · 2025
DOI 10.20944/preprints202506.0907.v1
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →